Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC
Status:
Terminated
Trial end date:
2019-12-18
Target enrollment:
Participant gender:
Summary
This study, BC-819-18-204, is a Phase 2, open-label, monotherapy, single-arm, multicenter
clinical trial of BC-819 (inodiftagene vixteplasmid) in patients with NMIBC adequately
treated with Bacillus Calmette-Guerin (BCG) whose disease is BCG unresponsive according to
the US Food and Drug Administration (FDA) guidance.